Answers are grounded in this paper and cite their sources.
Advances in targeted therapy have improved outcomes for patients with advanced epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC). Third-generation EGFR tyrosine kinase inhibitors and first-line combination regimens have expanded treatment options, making the balance between survival benefit, toxicity, treatment burden, and individual patient fitness increasingly important in initial treatment selection. As acquired resistance continues to limit the duration of benefit, this decision must also be considered in the context of subsequent care. At progression, tissue and plasma profiling provide complementary information that can help characterize the diverse mechanisms of resistance and guide further treatment. As resistance-directed therapies and antibody-drug conjugates expand the available treatment options, their selection requires consideration of prior therapy and the pattern of progression, together with molecular findings where relevant. This review examines these interconnected decisions across the course of advanced EGFR-mutant NSCLC, from first-line treatment selection to the assessment and management of acquired resistance. We also address central nervous system involvement, uncommon EGFR mutations, and exon 20 insertions as distinct clinical settings in which disease distribution and the underlying molecular alteration shape treatment choices. By integrating clinical and translational evidence, we discuss how these factors may inform treatment sequencing and individualized care, with attention to survival, quality of life, and the cumulative burden of therapy across the disease course.
No takes yet. Share an insight, caveat, or question.
Park et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: